Amelia W Maiga1,2, Stephen A Deppen1,2, Pierre P Massion3,4, Carol Callaway-Lane3, Rhonda Pinkerman5, Robert S Dittus1, Eric S Lambright5,2, Jonathan C Nesbitt5,2, Eric L Grogan5,2. 1. Geriatric Research Education and Clinical Center, Tennessee Valley Healthcare System, Nashville. 2. Department of Thoracic Surgery, Vanderbilt University Medical Center, Nashville, Tennessee. 3. Department of Medicine, Tennessee Valley Healthcare System, Nashville. 4. Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Department of Surgery, Tennessee Valley Healthcare System, Nashville.
Abstract
Importance: Clinical guidelines recommend that clinicians estimate the probability of malignancy for patients with indeterminate pulmonary nodules (IPNs) larger than 8 mm. Adherence to these guidelines is unknown. Objectives: To determine whether clinicians document the probability of malignancy in high-risk IPNs and to compare these quantitative or qualitative predictions with the validated Mayo Clinic Model. Design, Setting, and Participants: Single-institution, retrospective cohort study of patients from a tertiary care Department of Veterans Affairs hospital from January 1, 2003, through December 31, 2015. Cohort 1 included 291 veterans undergoing surgical resection of known or suspected lung cancer from January 1, 2003, through December 31, 2015. Cohort 2 included a random sample of 239 veterans undergoing inpatient or outpatient pulmonary evaluation of IPNs at the hospital from January 1, 2003, through December 31, 2012. Exposures: Clinician documentation of the quantitative or qualitative probability of malignancy. Main Outcomes and Measures: Documentation from pulmonary and/or thoracic surgery clinicians as well as information from multidisciplinary tumor board presentations was reviewed. Any documented quantitative or qualitative predictions of malignancy were extracted and summarized using descriptive statistics. Clinicians' predictions were compared with risk estimates from the Mayo Clinic Model. Results: Of 291 patients in cohort 1, 282 (96.9%) were men; mean (SD) age was 64.6 (9.0) years. Of 239 patients in cohort 2, 233 (97.5%) were men; mean (SD) age was 65.5 (10.8) years. Cancer prevalence was 258 of 291 cases (88.7%) in cohort 1 and 110 of 225 patients with a definitive diagnosis (48.9%) in cohort 2. Only 13 patients (4.5%) in cohort 1 and 3 (1.3%) in cohort 2 had a documented quantitative prediction of malignancy prior to tissue diagnosis. Of the remaining patients, 217 of 278 (78.1%) in cohort 1 and 149 of 236 (63.1%) in cohort 2 had qualitative statements of cancer risk. In cohort 2, 23 of 79 patients (29.1%) without any documented malignancy risk statements had a final diagnosis of cancer. Qualitative risk statements were distributed among 32 broad categories. The most frequently used statements aligned well with Mayo Clinic Model predictions for cohort 1 compared with cohort 2. The median Mayo Clinic Model-predicted probability of cancer was 68.7% (range, 2.4%-100.0%). Qualitative risk statements roughly aligned with Mayo predictions. Conclusions and Relevance: Clinicians rarely provide quantitative documentation of cancer probability for high-risk IPNs, even among patients drawn from a broad range of cancer probabilities. Qualitative statements of cancer risk in current practice are imprecise and highly variable. A standard scale that correlates with predicted cancer risk for IPNs should be used to communicate with patients and other clinicians.
Importance: Clinical guidelines recommend that clinicians estimate the probability of malignancy for patients with indeterminate pulmonary nodules (IPNs) larger than 8 mm. Adherence to these guidelines is unknown. Objectives: To determine whether clinicians document the probability of malignancy in high-risk IPNs and to compare these quantitative or qualitative predictions with the validated Mayo Clinic Model. Design, Setting, and Participants: Single-institution, retrospective cohort study of patients from a tertiary care Department of Veterans Affairs hospital from January 1, 2003, through December 31, 2015. Cohort 1 included 291 veterans undergoing surgical resection of known or suspected lung cancer from January 1, 2003, through December 31, 2015. Cohort 2 included a random sample of 239 veterans undergoing inpatient or outpatient pulmonary evaluation of IPNs at the hospital from January 1, 2003, through December 31, 2012. Exposures: Clinician documentation of the quantitative or qualitative probability of malignancy. Main Outcomes and Measures: Documentation from pulmonary and/or thoracic surgery clinicians as well as information from multidisciplinary tumor board presentations was reviewed. Any documented quantitative or qualitative predictions of malignancy were extracted and summarized using descriptive statistics. Clinicians' predictions were compared with risk estimates from the Mayo Clinic Model. Results: Of 291 patients in cohort 1, 282 (96.9%) were men; mean (SD) age was 64.6 (9.0) years. Of 239 patients in cohort 2, 233 (97.5%) were men; mean (SD) age was 65.5 (10.8) years. Cancer prevalence was 258 of 291 cases (88.7%) in cohort 1 and 110 of 225 patients with a definitive diagnosis (48.9%) in cohort 2. Only 13 patients (4.5%) in cohort 1 and 3 (1.3%) in cohort 2 had a documented quantitative prediction of malignancy prior to tissue diagnosis. Of the remaining patients, 217 of 278 (78.1%) in cohort 1 and 149 of 236 (63.1%) in cohort 2 had qualitative statements of cancer risk. In cohort 2, 23 of 79 patients (29.1%) without any documented malignancy risk statements had a final diagnosis of cancer. Qualitative risk statements were distributed among 32 broad categories. The most frequently used statements aligned well with Mayo Clinic Model predictions for cohort 1 compared with cohort 2. The median Mayo Clinic Model-predicted probability of cancer was 68.7% (range, 2.4%-100.0%). Qualitative risk statements roughly aligned with Mayo predictions. Conclusions and Relevance: Clinicians rarely provide quantitative documentation of cancer probability for high-risk IPNs, even among patients drawn from a broad range of cancer probabilities. Qualitative statements of cancer risk in current practice are imprecise and highly variable. A standard scale that correlates with predicted cancer risk for IPNs should be used to communicate with patients and other clinicians.
Authors: Michael K Gould; Tania Tang; In-Lu Amy Liu; Janet Lee; Chengyi Zheng; Kim N Danforth; Anne E Kosco; Jamie L Di Fiore; David E Suh Journal: Am J Respir Crit Care Med Date: 2015-11-15 Impact factor: 21.405
Authors: Christopher G Slatore; David H Au; Nancy Press; Renda Soylemez Wiener; Sara E Golden; Linda Ganzini Journal: Respir Med Date: 2015-01-27 Impact factor: 3.415
Authors: Jenny J Lin; Jessica Lake; Melanie M Wall; Andrew R Berman; John Salazar-Schicchi; Charles Powell; Steven M Keller; Ethan A Halm; Howard Leventhal; Juan P Wisnivesky Journal: J Thorac Oncol Date: 2014-09 Impact factor: 15.609
Authors: Susan Henderson; Amy DeGroff; Thomas B Richards; Julia Kish-Doto; Cindy Soloe; Christina Heminger; Elizabeth Rohan Journal: J Community Health Date: 2011-12
Authors: Carole A Ridge; Brian D Hobbs; Bolanle A Bukoye; Mark D Aronson; Phillip M Boiselle; Daniel A Leffler; Scot B Sternberg; David H Roberts Journal: J Comput Assist Tomogr Date: 2014 Jan-Feb Impact factor: 1.826
Authors: Neeti M Kanodra; Charlene Pope; Chanita H Halbert; Gerard A Silvestri; LaShanta J Rice; Nichole T Tanner Journal: Ann Am Thorac Soc Date: 2016-11
Authors: N Gómez-Sáez; I González-Álvarez; J Vilar; I Hernández-Aguado; M L Domingo; M F Lorente; M Pastor-Valero; L A Parker; N Picazo; J Calbo; B Lumbreras Journal: Eur Radiol Date: 2014-06-25 Impact factor: 5.315
Authors: Johanna Uthoff; Nicholas Koehn; Jared Larson; Samantha K N Dilger; Emily Hammond; Ann Schwartz; Brian Mullan; Rolando Sanchez; Richard M Hoffman; Jessica C Sieren Journal: Eur Radiol Date: 2019-04-01 Impact factor: 5.315
Authors: Michael N Kammer; Dianna J Rowe; Stephen A Deppen; Eric L Grogan; Alexander M Kaizer; Anna E Barón; Fabien Maldonado Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-09-02 Impact factor: 4.090
Authors: Michael N Kammer; Dhairya A Lakhani; Aneri B Balar; Sanja L Antic; Amanda K Kussrow; Rebekah L Webster; Shayan Mahapatra; Udaykamal Barad; Chirayu Shah; Thomas Atwater; Brenda Diergaarde; Jun Qian; Alexander Kaizer; Melissa New; Erin Hirsch; William J Feser; Jolene Strong; Matthew Rioth; York E Miller; Yoganand Balagurunathan; Dianna J Rowe; Sherif Helmey; Sheau-Chiann Chen; Joseph Bauza; Stephen A Deppen; Kim Sandler; Fabien Maldonado; Avrum Spira; Ehab Billatos; Matthew B Schabath; Robert J Gillies; David O Wilson; Ronald C Walker; Bennett Landman; Heidi Chen; Eric L Grogan; Anna E Barón; Darryl J Bornhop; Pierre P Massion Journal: Am J Respir Crit Care Med Date: 2021-12-01 Impact factor: 30.528
Authors: Pierre P Massion; Sanja Antic; Sarim Ather; Carlos Arteta; Jan Brabec; Heidi Chen; Jerome Declerck; David Dufek; William Hickes; Timor Kadir; Jonas Kunst; Bennett A Landman; Reginald F Munden; Petr Novotny; Heiko Peschl; Lyndsey C Pickup; Catarina Santos; Gary T Smith; Ambika Talwar; Fergus Gleeson Journal: Am J Respir Crit Care Med Date: 2020-07-15 Impact factor: 21.405